Login to Your Account

Centocor RA Drug Succeeds in Three Phase III Trials

By Donna Young

Thursday, June 12, 2008
Centocor Inc. and its partner Schering-Plough Corp. said their investigational rheumatoid arthritis drug golimumab (CNTO 148), a next-generation human antitumor necrosis factor (TNF)-alpha monoclonal antibody, met its primary endpoint in three separate Phase III studies. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription